Cargando…
In vitro-engineered non-antibody protein therapeutics
Antibodies have proved to be a valuable mode of therapy for numerous diseases, mainly owing to their high target binding affinity and specificity. Unfortunately, antibodies are also limited in several respects, chief amongst those being the extremely high cost of manufacture. Therefore, non-antibody...
Autores principales: | Simeon, Rudo, Chen, Zhilei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Higher Education Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777970/ https://www.ncbi.nlm.nih.gov/pubmed/28271446 http://dx.doi.org/10.1007/s13238-017-0386-6 |
Ejemplares similares
-
A Screen for Genetic Suppressor Elements of Hepatitis C Virus Identifies a Supercharged Protein Inhibitor of Viral Replication
por: Simeon, Rudo L., et al.
Publicado: (2013) -
Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027
por: Peng, Zeyu, et al.
Publicado: (2019) -
De Novo Isolation & Affinity Maturation of yeast-displayed Virion-binding human fibronectin domains by flow cytometric screening against Virions
por: Heinzelman, Pete, et al.
Publicado: (2019) -
Engineering therapeutic antibodies targeting G-protein–coupled receptors
por: Jo, Migyeong, et al.
Publicado: (2016) -
Engineering antibody and protein therapeutics to cross the blood–brain barrier
por: Zhao, Peng, et al.
Publicado: (2022)